{"id":46301,"date":"2022-07-19T11:02:21","date_gmt":"2022-07-19T09:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/"},"modified":"2022-07-19T11:02:21","modified_gmt":"2022-07-19T09:02:21","slug":"ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/","title":{"rendered":"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology"},"content":{"rendered":"
\n

VIENNA, Austria–(BUSINESS WIRE)–Ribbon Biolabs, the DNA synthesis company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1<\/a><\/span>, covering Ribbon Biolabs\u2019 novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOur novel method of fast, accurate, cost-effective DNA synthesis constitutes the basis of Ribbon Biolabs\u2019 proprietary capabilities, and the grant of this patent serves as a validation of our highly differentiated solution for synthetic biology,\u201d commented Harold P. de Vladar, CEO and founder of Ribbon Biolabs<\/b>. \u201cPrevious methods for automated DNA synthesis have been limited in their applicability due to restricted lengths possible to produce and extended development timelines. We look forward to the further expansion of our intellectual property portfolio and our growing collaborations focused on driving innovation in the biotechnology, biopharma and academic research arenas.\u201d\n<\/p>\n

\nRibbon Biolabs\u2019 novel approach to synthesizing DNA as described in the patent comprises a pre-built library of oligonucleotides, or shorter genetic sequences, that has been streamlined for efficient access, with reduced time and cost constraints that are further enhanced by an assembly workflow producing long polynucleotides accurately and without mismatches. This method optimizes the throughput time required to synthesize target DNA which has enabled the company to produce lengths beyond 10,000 base pairs efficiently and with high speed, including the recent successful synthetization of a 20,000 bp molecule for an undisclosed pharma client.\n<\/p>\n

\nAbout Ribbon Biolabs
\n
<\/b>Ribbon Biolabs is a synthetic biology company advancing a new technology for the automated synthesis of long DNA molecules to enable innovation in the life sciences. With its proprietary technology in place, Ribbon Biolabs aims to be an inflection point in the continuing growth of the Bio-Economy by becoming the leading partner for long DNA molecules.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRibbon Biolabs<\/b>
Gabriele Schaller
\n
PR@ribbonbiolabs.com<\/a><\/p>\n

Trophic Communications<\/b>
Eva Mulder or Joel Hornby
\n
+31 6 52 33 15 79 or +49 160 9081 6161
\n
ribbon@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VIENNA, Austria–(BUSINESS WIRE)–Ribbon Biolabs, the DNA synthesis company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs\u2019 novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46301","6":"format-standard","7":"category-industry"},"yoast_head":"\nRibbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"VIENNA, Austria–(BUSINESS WIRE)–Ribbon Biolabs, the DNA synthesis company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs\u2019 novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-19T09:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220719005064\/en\/1514882\/21\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology\",\"datePublished\":\"2022-07-19T09:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/\"},\"wordCount\":361,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005064\\\/en\\\/1514882\\\/21\\\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/\",\"name\":\"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005064\\\/en\\\/1514882\\\/21\\\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg\",\"datePublished\":\"2022-07-19T09:02:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005064\\\/en\\\/1514882\\\/21\\\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005064\\\/en\\\/1514882\\\/21\\\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/","og_locale":"en_US","og_type":"article","og_title":"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology - Pharma Trend","og_description":"VIENNA, Austria–(BUSINESS WIRE)–Ribbon Biolabs, the DNA synthesis company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs\u2019 novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-19T09:02:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220719005064\/en\/1514882\/21\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology","datePublished":"2022-07-19T09:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/"},"wordCount":361,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005064\/en\/1514882\/21\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/","url":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/","name":"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005064\/en\/1514882\/21\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg","datePublished":"2022-07-19T09:02:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220719005064\/en\/1514882\/21\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220719005064\/en\/1514882\/21\/Ribbon_Biolabs_Logotype_RGB_Blue_Red.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ribbon-biolabs-establishes-ip-portfolio-with-first-granted-u-s-patent-covering-fast-cost-effective-long-dna-synthesis-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46301"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46301\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}